Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03835481 |
| Consolidated Lead Sponsor | Boehringer Ingelheim |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 165 participants (ACTUAL) |
| Registered Start Date | 2019-03-18 |
| WhyStopped Classification | Strategic / Business / Sponsor Decision |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Dermatology Research Associates | Los Angeles, CA | Open Hospital Dossier -> |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, IN | Open Hospital Dossier -> |
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.